{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adalimumab", "query": { "intervention": "Adalimumab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 219, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adalimumab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T02:19:24.977Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00932113", "title": "Mechanism of Action Study for Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Adalimumab (Humira)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tufts Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 33, "start_date": "2009-06", "completion_date": "2017-05-01", "has_results": true, "last_update_posted_date": "2017-08-31", "last_synced_at": "2026-09-02T02:19:24.977Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00932113" }, { "nct_id": "NCT01877668", "title": "Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Tofacitinib 5 mg BID", "type": "DRUG" }, { "name": "Tofacitinib 10 mg BID", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 422, "start_date": "2014-01-20", "completion_date": "2015-12-18", "has_results": true, "last_update_posted_date": "2017-07-06", "last_synced_at": "2026-09-02T02:19:24.977Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01877668" }, { "nct_id": "NCT05460390", "title": "Proactive Therapeutic Drug Monitoring Based Adalimumab Therapy Optimization in Patients With Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Therapeutic drug monitoring (TDM)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-10-26", "completion_date": "2024-06-30", "has_results": false, "last_update_posted_date": "2024-07-10", "last_synced_at": "2026-09-02T02:19:24.977Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05460390" }, { "nct_id": "NCT04551352", "title": "A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Melanoma", "Uveal Melanoma", "Mucosal Melanoma" ], "interventions": [ { "name": "RO7293583", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-10-28", "completion_date": "2022-07-28", "has_results": false, "last_update_posted_date": "2022-10-03", "last_synced_at": "2026-09-02T02:19:24.977Z", "location_count": 4, "location_summary": "Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04551352" }, { "nct_id": "NCT00814255", "title": "Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Focal Segmental Glomerulosclerosis" ], "interventions": [ { "name": "Adalimumab", "type": "DRUG" }, { "name": "Lisinopril, losartan, and atorvastatin", "type": "DRUG" }, { "name": "galactose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "65 Years", "sex": "ALL", "summary": "1 Year to 65 Years" }, "enrollment_count": 32, "start_date": "2008-12", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2016-07-11", "last_synced_at": "2026-09-02T02:19:24.977Z", "location_count": 17, "location_summary": "Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00814255" }, { "nct_id": "NCT01752855", "title": "Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "New formulation adalimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2012-12", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2014-10-29", "last_synced_at": "2026-09-02T02:19:24.977Z", "location_count": 6, "location_summary": "Mesa, Arizona • Hemet, California • Wichita, Kansas + 3 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Hemet", "state": "California" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Clifton", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01752855" }, { "nct_id": "NCT01712178", "title": "A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Adalimumab, current formulation", "type": "BIOLOGICAL" }, { "name": "Adalimumab, new formulation", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2012-06", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2014-06-11", "last_synced_at": "2026-09-02T02:19:24.977Z", "location_count": 6, "location_summary": "Mesa, Arizona • Hemet, California • Wichita, Kansas + 3 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Hemet", "state": "California" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Clifton", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01712178" }, { "nct_id": "NCT01870986", "title": "Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-06410293", "type": "BIOLOGICAL" }, { "name": "Humira (adalimumab-EU)", "type": "BIOLOGICAL" }, { "name": "Humira (adalimumab-US)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 210, "start_date": "2013-05", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2014-02-14", "last_synced_at": "2026-09-02T02:19:24.977Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01870986" }, { "nct_id": "NCT02332590", "title": "Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Placebo (for sarilumab)", "type": "DRUG" }, { "name": "Placebo (for adalimumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 369, "start_date": "2015-01-28", "completion_date": "2020-12-29", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-09-02T02:19:24.977Z", "location_count": 17, "location_summary": "Covina, California • Long Beach, California • Whittier, California + 14 more", "locations": [ { "city": "Covina", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02332590" }, { "nct_id": "NCT03056924", "title": "Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Inflammatory Bowel Diseases" ], "interventions": [ { "name": "Pneumococcal Pneumonia vaccine", "type": "BIOLOGICAL" }, { "name": "Influenza vaccine", "type": "BIOLOGICAL" }, { "name": "Hepatitis B vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Boston Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 173, "start_date": "2017-07-05", "completion_date": "2019-01-15", "has_results": false, "last_update_posted_date": "2019-12-30", "last_synced_at": "2026-09-02T02:19:24.977Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03056924" } ] }